Literature DB >> 17194664

Favourable outcome in an APL patient with PLZF/RARalpha fusion gene: quantitative real-time RT-PCR confirms molecular response.

Bruno Cassinat1, Isabelle Guillemot, Cécile Moluçon-Chabrot, Fabien Zassadowski, Pierre Fenaux, Olivier Tournilhac, Christine Chomienne.   

Abstract

Rare cases of acute promyelocytic leukemia (APL) are associated with a t(11;17) translocation and a PLZF-RARalpha fusion transcript. Because of molecular specificities of the fusion protein, ATRA efficiency is often reduced in these cases. We present herein the case of an 83-year old patient which has been successfully treated by ATRA and Daunorubicin. The described quantitative RT-PCR method allowed successful monitoring and confirmation of the molecular response.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17194664

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  4 in total

1.  Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting.

Authors:  Rihab Nasr; Hugues de Thé
Journal:  Int J Hematol       Date:  2010-05-11       Impact factor: 2.490

2.  Development of real-time quantitative polymerase chain reaction assays to track treatment response in retinoid resistant acute promyelocytic leukemia.

Authors:  Jelena V Jovanovic; Kristian Rennie; Dominic Culligan; Andrew Peniket; Anne Lennard; Justin Harrison; Paresh Vyas; David Grimwade
Journal:  Front Oncol       Date:  2011-10-25       Impact factor: 6.244

Review 3.  Characterization of atypical acute promyelocytic leukaemia: Three cases report and literature review.

Authors:  Xiaoxue Wang; Jing Wang; Lijun Zhang
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

Review 4.  PLZF-RARα, NPM1-RARα, and Other Acute Promyelocytic Leukemia Variants: The PETHEMA Registry Experience and Systematic Literature Review.

Authors:  Marta Sobas; Maria Carme Talarn-Forcadell; David Martínez-Cuadrón; Lourdes Escoda; María J García-Pérez; Jose Mariz; María J Mela-Osorio; Isolda Fernández; Juan M Alonso-Domínguez; Javier Cornago-Navascués; Gabriela Rodríguez-Macias; María E Amutio; Carlos Rodríguez-Medina; Jordi Esteve; Agnieszka Sokół; Thais Murciano-Carrillo; María J Calasanz; Manuel Barrios; Eva Barragán; Miguel A Sanz; Pau Montesinos
Journal:  Cancers (Basel)       Date:  2020-05-21       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.